IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Prodrug Design and Development: An Evolving Strategy in Drug Delivery

Trupti Sayaji Wayal, Gayatri Kashinath Wani, Ashwini Shankar Bere,

Gauri Bappasaheb Kokate, Supriya Sunil Shinde

Student

Dr. Babasaheb Ambedkar Technological University Lonere - Raigad, Maharastra

Abstract

Prodrugs are pharmacologically inactive compounds that undergo metabolic conversion within the body to release an active drug. They are an essential strategy in drug design, particularly for improving bioavailability, solubility, stability, and tissue-specific targeting. The process of converting a parent drug into a prodrug and subsequently activating it in the body allows for better therapeutic efficacy while reducing toxicity. This review provides a comprehensive overview of prodrug design, classification, prodrug development, challenges, and strategies of drug design. Despite the significant progress in prodrug design, there remain several challenges that require innovative solutions. Future directions suggest a promising evolution in the design and application of prodrugs to enhance therapeutic outcomes.

Keywords

Prodrug, Enzyme, Strategies, Development, Identification, Design, Selection, In-vitro, In-vivo, Optimization, Clinical, Preclinical

Introduction

Prodrugs, a concept pioneered by Albert in 1958 [1], have revolutionized the field of pharmaceutical research, offering a promising strategy to overcome the limitations of conventional drugs [2]. By design, prodrugs are inactive analogs of pharmacologically active compounds, which undergo in vivo biotransformation to release the parent drug, thereby enhancing its efficacy, safety, and bioavailability [3]. This innovative approach has been instrumental In addressing issues related to poor solubility, inadequate pharmacokinetics, and undesirable side effects, significantly improving the therapeutic index of various medications [4]. Over the past few decades, prodrug design and development have evolved rapidly, driven by advances in medicinal chemistry, pharmacology,

and biotechnology [5]. The prodrug strategy has been successfully applied to various therapeutic areas, including anticancer [6], antiviral [7], and anti-inflammatory agents [8], as well as central nervous system (CNS) targeted therapies [9]. Moreover, the emergence of novel prodrug technologies, such as enzyme-activated prodrugs [10] and stimuli-responsive prodrugs [11], has further expanded the scope of this field. Despite significant progress, prodrug development still faces challenges, including optimizing prodrug stability, improving bioconversion efficiency, and minimizing toxicity [12]. Therefore, ongoing research focuses on designing and synthesizing novel prodrugs that can effectively overcome these hurdles and provide enhanced therapeutic outcomes. This review aims to provide a comprehensive overview of the current state of prodrug design and development, highlighting recent advances, challenges, and future directions in this dynamic field.

History of Prodrug

The concept of prodrugs has a rich history that spans over six decades. The earliest example of prodrug design dates back to the 1950s with the development of sulfasalazine, a prodrug of 5aminosalicylic acid, for the treatment of ulcerative colitis [13]. In the 1970s, Albert formally introduced the term "prodrug," and the concept gained widespread attention [13]. The 1980s saw significant advancements in prodrug design, particularly with the development of targeted prodrugs, such as glucuronide prodrugs for colon-specific delivery [13]. The 1990s witnessed the emergence of novel prodrug strategies, Including the use of peptide-based prodrugs and virustargeted prodrugs [13]. These innovations paved the way for further research and development in the field. In recent years, prodrug design has continued to evolve, incorporating cutting-edge technologies such as nanotechnology, stimuli-responsive materials, and artificial intelligence [9,13,25]. Today, prodrugs remain a vital tool in pharmaceutical development, offering improved bioavailability, targeted delivery, and enhanced efficacy.

Classification of prodrug

1)Enzyme Activated Prodrug

Enzyme-activated prodrugs are a class of prodrugs that require enzymatic activation to release the active drug [2]. These prodrugs are designed to exploit specific enzymes present in the target tissue or cells, thereby minimizing systemic side effects [4]. By leveraging enzyme specificity, enzymeactivated prodrugs can achieve targeted delivery, reducing toxicity and improving efficacy. The activation of enzyme-activated prodrugs involves a specific enzyme-catalyzed reaction that converts the prodrug into its active form [11]. This reaction can occur through various enzymatic mechanisms, including hydrolysis, oxidation, or reduction. For instance, acyclovir, an antiviral prodrug, is activated by thymidine kinase in infected cells [2]. While capecitabine, an anticancer prodrug, is activated by thymidylate phosphorylase in tumor tissues [14].

Enzyme-activated prodrugs offer several advantages, including targeted therapy, reduced side effects, improved efficacy, and enhanced bioavailability [3]. By localizing drug activation to the target site, these prodrugs minimize exposure to healthy tissues, reducing the risk of adverse effects. Furthermore, enzyme-activated prodrugs can be designed to exploit specific enzyme expression patterns in disease tissues, enhancing selectivity and potency. However, enzymeactivated prodrugs also face challenges, such as enzyme variability, potential enzyme inhibition, and limited enzyme specificity [15]. Variability in enzyme expression or activity can impact prodrug activation, while enzyme inhibitors can compromise prodrug efficacy. Additionally, offtarget activation can occur if the activating enzyme is present in non-target tissues.

Several enzymes are involved in the activation of enzyme-activated prodrugs, including carboxylesterases, thymidine kinase, thymidylate phosphorylase, cytochrome P450 enzymes, and glutathione S-transferases [4]. Understanding the enzymology of prodrug activation is crucial for designing effective and selective enzyme-activated prodrugs. Examples of enzyme-activated prodrugs include acyclovir, capecitabine, irinotecan, and CPT-

11 [11]. These prodrugs have demonstrated improved efficacy and reduced toxicity in various therapeutic applications, highlighting the potential of enzyme-activated prodrugs in targeted therapy.

2) Non- Enzyme Activated Prodrug

Non-enzyme activated prodrugs are a class of prodrugs that undergo chemical transformation without the need for enzymatic activation, releasing the active drug through non-enzymatic reactions [15]. These reactions can be triggered by changes in pH, temperature, or ionic strength, allowing for controlled release of the active compound. The design of non-enzyme activated prodrugs exploits specific chemical reactions, such as hydrolysis, reduction, or oxidation, to release the active drug [3]. For example, Carmustine, an anticancer agent, undergoes nonenzymatic chemical activation in the bloodstream through a pH-dependent hydrolysis reaction [11]. Non-enzyme activated prodrugs offer several advantages, including improved bioavailability, reduced toxicity, and enhanced efficacy [2]. Additionally, these prodrugs can bypass enzymerelated variability and inhibition, providing a more predictable and consistent therapeutic response. Examples of non-enzyme activated prodrugs include Carmustine, Lomustine, Fotemustine, and Temozolomide, all of which are used in cancer therapy [4]. Researchers continue to explore novel prodrug designs that exploit specific chemical reactions or environmental triggers to improve therapeutic outcomes.

3) Targeted Activation Prodrug

Targeted activation prodrugs are a class of prodrugs designed to release the active drug specifically at the site of action, minimizing systemic side effects and improving therapeutic efficacy [14]. These prodrugs exploit specific enzymes or biochemical processes present in the target tissue or cells, ensuring that the active drug is released only where it is needed. There are several types of targeted activation prodrugs, including enzyme-targeted prodrugs, pH-targeted prodrugs, and receptor-targeted prodrugs. Enzyme-targeted prodrugs utilize specific enzymes overexpressed in diseased tissues to activate the prodrug [11]. For example, capecitabine, an anticancer prodrug, is activated by thymidylate phosphorylase, an enzyme overexpressed in tumor tissues. pH-targeted prodrugs exploit differences in pH between healthy and diseased tissues to release the active drug. Temozolomide, an anticancer prodrug, is an example of this approach, releasing its active form in the acidic environment of tumor tissues [3]. Receptor-targeted prodrugs bind to specific receptors overexpressed on diseased cells, releasing the active drug upon internalization. This approach has shown promise in cancer therapy, where targeted prodrugs can selectively kill tumor cells while sparing healthy tissues [2].

The advantages of targeted activation prodrugs are numerous. They offer improved therapeutic efficacy, reduced systemic toxicity, and enhanced specificity. By minimizing exposure to healthy tissues, targeted prodrugs reduce the risk of adverse effects and improve patient outcomes. Examples of targeted activation prodrugs include capecitabine, irinotecan, and temozolomide, all of which have demonstrated improved efficacy and reduced toxicity in cancer therapy [14,11,3].

Strategies of Prodrug Design And Development

1)Chemical Modification Strategies

Chemical modification strategies are essential in prodrug design, enabling researchers to optimize prodrug properties and enhance therapeutic efficacy. These strategies involve modifying the chemical structure of the active drug to improve its solubility, stability, and bioavailability. One common chemical modification strategy is esterification, which involves conjugating the active drug to a promoiety via an ester linkage. This approach can improve solubility and stability while also facilitating enzymatic activation [2]. For example, the anticancer prodrug capecitabine utilizes an ester linkage to conjugate the active drug, 5-fluorouracil, to a promoiety. Amidation is another chemical modification strategy, involving conjugation of the active drug to a promoiety via

an amide linkage. This approach can enhance stability and bioavailability [3]. The anticancer prodrug, irinotecan, utilizes amidation to conjugate the active drug to a promoiety.

Lipophilic and hydrophilic modifications involve incorporating lipophilic or hydrophilic groups to modify the prodrug's physicochemical properties. Lipophilic groups can enhance membrane permeability, while hydrophilic groups can improve aqueous solubility [11] Redox-based chemical modification strategies involve incorporating redox-sensitive groups to facilitate activation in specific environments. For instance, the anticancer prodrug, tirapazamine, utilizes a redoxsensitive group to activate in hypoxic tumor environments. Phosphorylation and dephosphorylation strategies involve modifying the active drug with phosphate groups to improve solubility and stability. The antiviral prodrug, tenofovir disoproxil fumarate, utilizes phosphorylation to enhance its oral bioavailability. Cyclodextrin-based chemical modification strategies involve conjugating the active drug to cyclodextrins to improve solubility and stability. The anticancer prodrug, doxorubicin, utilizes cyclodextrin conjugation to enhance its solubility.

2) Enzyme Activated Prodrug Strategies

Enzyme-activated prodrugs are a class of prodrugs designed to exploit specific enzymes present in diseased tissues, thereby minimizing systemic side effects. This strategy involves conjugating the active drug to a promoiety that can be cleaved by a specific enzyme, releasing the active drug at the site of action [14]. Enzyme-activated prodrugs have shown promise in cancer therapy, where they can selectively target tumor tissues and reduce toxicity to healthy tissues. The design of enzyme-activated prodrugs requires careful consideration of enzyme specificity, promoiety design, and linker chemistry [11]. Enzymes such as thymidylate phosphorylase, carboxylesterase, and cytochrome P450 have been exploited in enzyme-activated prodrug design. For example, capecitabine, an anticancer prodrug, is activated by thymidylate phosphorylase, which is overexpressed in tumor tissues [3]. The benefits of enzyme-activated prodrugs include improved specificity, reduced systemic toxicity, and enhanced therapeutic efficacy [2]. However, challenges remain, including enzyme variability and polymorphism, enzyme inhibition, and resistance [4]. Recent advances in enzyme-activated prodrug design include the development of nanotechnologybased prodrugs and gene-directed enzyme prodrug therapy (GDEPT) [11]. These approaches hold promise for improving the efficacy and specificity of enzyme-activated prodrugs.

3) Targeted Prodrug Strategies

Targeted prodrugs are a class of prodrugs designed to deliver drugs specifically to diseased tissues or cells, minimizing systemic toxicity and enhancing therapeutic efficacy [16]. These prodrugs utilize targeting moieties that recognize and bind to specific molecular markers or receptors overexpressed in diseased tissues. Antibody-directed enzyme prodrug therapy (ADEPT) and genedirected enzyme prodrug therapy (GDEPT) are two prominent strategies employed in targeted prodrug design. The design of targeted prodrugs requires careful consideration of targeting moiety design and specificity, enzyme-prodrug interaction, and pharmacokinetics and biodistribution [11]. Capecitabine, an anticancer prodrug, targets thymidylate phosphorylase in tumor tissues, demonstrating improved specificity and reduced systemic toxicity. Targeted prodrugs offer several benefits, including enhanced therapeutic efficacy, reduced systemic toxicity, and potential for combination therapies [3]. However, challenges remain, such as targeting moiety optimization, enzyme-prodrug interaction optimization, and clinical translation. Recent advances in targeted prodrug design include the development of nanotechnology-based prodrugs and receptor-targeted prodrugs [2]. These approaches hold promise for improving the efficacy and specificity of targeted prodrugs.

4) Stimuli-Responsive Prodrug Strategies

Stimuli-responsive prodrugs are a class of prodrugs designed to respond to specific physiological or environmental stimuli, releasing the active drug in a controlled and targeted manner [11]. This strategy enhances

therapeutic efficacy while minimizing systemic toxicity. Stimuli-responsive prodrugs can be classified into four main categories: pH-responsive, temperature-responsive, enzyme-responsive, and light-responsive prodrugs. pH-responsive prodrugs exploit differences in pH between healthy and diseased tissues, allowing for targeted drug release [17]. For example, doxorubicin prodrugs have been designed to release the active drug in acidic tumor environments. Enzyme-responsive prodrugs, on the other hand, leverage specific enzymes overexpressed in diseased tissues to activate the prodrug [9]. The design of stimuli-responsive prodrugs requires careful consideration of stimuli-responsive moiety design, prodrug stability, and pharmacokinetics [18]. Benefits of stimuli-responsive prodrugs include enhanced therapeutic efficacy, reduced systemic toxicity, and improved patient compliance.

Challenges and future directions in stimuli-responsive prodrug development include stimuliresponsive moiety optimization, prodrug stability and scalability, and clinical translation [2]. Despite these challenges, stimuli-responsive prodrugs hold promise for improving treatment outcomes in various diseases.

5) Computational Prodrug Design Strategies

Computational prodrug design strategies have revolutionized the field of prodrug development, enabling researchers to design and optimize prodrugs with improved efficacy and reduced toxicity [11]. These strategies utilize computational models and algorithms to predict prodrug properties, simulate metabolism, and identify optimal prodrug candidates. Molecular modeling, quantitative structure-activity relationship (QSAR) analysis, pharmacophore modeling, and molecular docking are some of the key computational tools employed in prodrug design. The application of computational prodrug design has led to the development of successful prodrugs, such as anticancer prodrugs targeting thymidylate phosphorylase (TP) [11]. QSAR analysis has also been employed to design prodrugs for HIV protease inhibition [9]. These studies demonstrate the potential of computational prodrug design to enhance prodrug efficacy and minimize toxicity.

The benefits of computational prodrug design include enhanced predictive power, reduced experimental costs, improved prodrug efficacy, and minimized toxicity [18]. However, challenges remain, such as integrating computational models with experimental data and accounting for prodrug metabolism and pharmacokinetics. Future directions in computational prodrug design include the development of novel computational tools and the integration of artificial intelligence and machine learning algorithms [2]. These advancements hold promise for improving prodrug design and development.

Development process of prodrug design

1)Target Identification and Selection

Target identification and selection is a critical step in prodrug design, requiring a comprehensive understanding of the disease biology and the molecular mechanisms involved. The process begins with identifying potential targets, which can be achieved through genomic analysis, protein structure determination, and high-throughput screening [19]. Once potential targets are identified, they must be evaluated for druggability, specificity, potency, and safety [21].

The druggability of a target refers to its ability to be modulated by a small molecule, and can be assessed through structural biology and computational modeling [22]. Specificity is also crucial, as off-target effects can lead to adverse reactions and reduced efficacy [17]. Potency, or the ability of the prodrug to modulate the target, must also be evaluated, along with safety considerations, such as potential toxicity and side effects. Target validation involves confirming the relevance of the selected target to the disease, through in vitro and in vivo studies, as

well as clinical validation [19]. Bioinformatics tools, such as genomic and proteomic analysis, can also be employed to support target validation [20].

In the context of prodrug design, target identification and selection must also consider the enzyme or activation mechanism responsible for converting the prodrug to its active form [3]. This requires an understanding of the enzyme's substrate specificity, expression levels, and localization [24].

2) Prodrug Candidate Selection

Prodrug candidate selection is a critical step in prodrug development, requiring careful evaluation of various factors to identify promising candidates. The selection process typically begins with a thorough analysis of the parent drug's properties, including its pharmacokinetic and pharmacodynamic profile, solubility, permeability, and metabolic stability [23]. Candidates with poor aqueous solubility, low oral bioavailability, or extensive first-pass metabolism are often prioritized for prodrug development.

Next, potential prodrug candidates are evaluated based on their chemical structure, molecular weight, and functional groups [24]. The promoiety, or masking group, is selected based on its ability to improve the parent drug's properties, such as enhancing solubility or reducing toxicity [3]. The linker chemistry connecting the promoiety to the parent drug is also crucial, as it affects the prodrug's stability, activation rate, and pharmacokinetic profile.

In vitro and in vivo studies are conducted to assess the prodrug candidate's efficacy, safety, and pharmacokinetic properties [22]. These studies help identify potential issues related to prodrug activation, metabolism, and distribution. Computational modeling and simulation tools, such as molecular docking and pharmacokinetic modeling, can also support prodrug candidate selection.

Several factors influence prodrug candidate selection, including:

a) Disease target and pathology
b) Parent drug properties and limitations
c) Promoiety selection and linker chemistry
d) Pharmacokinetic and pharmacodynamic profile
e) Safety and toxicity considerations

3) Prodrug Design and Synthesis

Prodrug design and synthesis are critical steps in prodrug development, requiring careful consideration of various factors to create an effective and safe prodrug. The design process typically begins with a thorough analysis of the parent drug's properties, including its pharmacokinetic and pharmacodynamic profile, solubility, permeability, and metabolic stability [23]. Based on this analysis, the promoiety, or masking group, is selected to improve the parent drug's properties.

Various prodrug design strategies are employed, including:

a) Chemical modification: altering the parent drug's chemical structure to improve solubility or permeability [24].
b) Enzyme-targeted prodrugs: designing prodrugs that are activated by specific enzymes overexpressed in disease tissues [3].
c) Stimuli-responsive prodrugs: designing prodrugs that respond to specific environmental stimuli, such as pH or temperature changes [22].

Synthesis of the prodrug involves linking the promoiety to the parent drug using various chemical reactions, such as esterification, amidation, or click chemistry [25]. The resulting prodrug is then evaluated for its physicochemical properties, stability, and pharmacokinetic profile.

Key considerations in prodrug design and synthesis include:

a) Promoiety selection and linker chemistry.
b) Enzyme specificity and activation rate.
c) Pharmacokinetic and pharmacodynamic profile.
d) Stability and solubility.
e) Safety and toxicity.

4) In vitro Evaluation

In vitro evaluation plays a crucial role in prodrug development, providing valuable insights into the prodrug's pharmacokinetic and pharmacodynamic properties. These studies assess the prodrug's stability, solubility, permeability, and metabolic activation. Stability studies investigate the prodrug's degradation rate and pathways under various conditions, such as pH, temperature, and light exposure [23]. Solubility assessments determine the prodrug's ability to dissolve in aqueous solutions, impacting bioavailability [24]. Permeability studies evaluate the prodrug's ability to cross biological membranes, influencing absorption and distribution [3]. Metabolic activation studies investigate the prodrug's conversion to its active form, assessing enzyme specificity and efficiency. Cell-based assays assess the prodrug's cytotoxicity, efficacy, and mechanism of action [22]. Enzyme assays evaluate the prodrug's activation by specific enzymes, confirming target specificity.

Key in vitro evaluation parameters:

a) Stability and solubility
b) Permeability and absorption
c) Metabolic activation and enzyme specificity
d) Cytotoxicity and efficacy
e) IVIVC

5) In vivo Evaluation

In vivo evaluation is a critical step in prodrug development, assessing the prodrug's pharmacokinetic and pharmacodynamic properties in a biological system. These studies investigate the prodrug's absorption, distribution, metabolism, and elimination (ADME) profile. Pharmacokinetic studies evaluate the prodrug's bioavailability, half-life, and clearance, providing insights into its systemic exposure [23]. Biodistribution studies assess the prodrug's tissue distribution and targeting efficiency. Efficacy studies investigate the prodrug's therapeutic potential in relevant disease models, evaluating its ability to modulate the target pathway [24].

Toxicity studies assess the prodrug's safety profile, identifying potential adverse effects.

In vivo models used:

a) Rodent models (mice, rats)
b) Non-rodent models (dogs, monkeys)
c) Transgenic and knockout models
d) Humanized mouse models

6) Optimization and refinement

Optimization and refinement are critical steps in prodrug development, focusing on enhancing the prodrug's efficacy, safety, and pharmacokinetic profile. This process involves iterative design, synthesis, and evaluation of prodrug candidates. Structural optimization involves modifying the prodrug's chemical structure to improve its stability, solubility, and permeability [23]. This can include altering the promoiety, linker chemistry, or parent drug structure. Pharmacokinetic optimization focuses on enhancing the prodrug's absorption, distribution, metabolism, and elimination (ADME) profile [24]. This may involve modifying the prodrug's lipophilicity, molecular weight, or enzyme specificity.

Formulation optimization involves developing suitable formulations to enhance the prodrug's bioavailability and stability [3]. This can include solid-state formulations, nanoparticles, or liposomes. Biological optimization assesses the prodrug's efficacy and safety in relevant disease models, guiding lead optimization [22]. This includes evaluating the prodrug's potency, selectivity, and toxicity. Computational modeling and simulation tools support prodrug optimization, predicting pharmacokinetic and pharmacodynamic properties [25].

Key optimization and refinement strategies:

a) Structural optimization
b) Pharmacokinetic optimization
c) Formulation optimization
d) Biological optimization
e) Computational modeling

7) Preclinical and Clinical Development of Prodrug

Preclinical development for prodrugs involves comprehensive in vitro and in vivo studies to assess their pharmacokinetic, pharmacodynamic, and toxicological properties. This phase includes:

a) ADME (absorption, distribution, metabolism, and elimination) studies to evaluate prodrug stability and conversion to the active form.
b) Toxicity studies to assess safety and potential side effects.
c) Efficacy studies in relevant disease models to demonstrate therapeutic potential.
d) and pharmacodynamic modeling to predict human dosing.

Clinical development for prodrugs involves human trials to evaluate safety, efficacy, and optimal dosing.

Phase I trials assess prodrug safety, tolerability, and pharmacokinetics in healthy volunteers or patients.

Phase II trials evaluate prodrug efficacy, optimal dosing, and safety in larger patient populations.

Phase III trials confirm prodrug efficacy, safety, and compare with existing treatments. [26,27]

Challenges

1. Predicting prodrug stability and conversion to the active form.
2. Optimizing prodrug pharmacokinetics and pharmacodynamics.
3. Ensuring target specificity and minimizing off-target effects.
4. Overcoming biological barriers (e.g., blood-brain barrier).
5. Scaling up synthesis and manufacturing.

Limitations

1. Limited understanding of enzyme-specificity and expression.
2. Difficulty in predicting human pharmacokinetics from preclinical models.
3. Potential for adverse effects due to prodrug or metabolites.
4. High development costs and timelines.
5. Regulatory hurdles and intellectual property concerns.

Specific Challenges

1. Linker chemistry instability (Rautio et al., 2008).
2. Enzyme-specific activation (Testa et al., 2010).
3. Pharmacokinetic variability (Stella et al., 2007).
4. Immunogenicity and hypersensitivity reactions (Li et al., 2019).

Future Directions

1. Advanced computational modeling and simulation.
2. Novel linker chemistries and enzyme-specific prodrugs.
3. Biomarker-driven prodrug development.
4. Combination therapies and prodrug conjugates.

Conclusion

Prodrugs represent a powerful strategy in modern drug development, offering the potential to improve drug bioavailability, solubility, and tissue-specific targeting. While the challenges in metabolic activation, variability in enzymatic processes, and toxicity remain significant, the future of prodrug design looks promising with innovations in nanotechnology, personalized medicine, and enzyme-targeting strategies. With these advancements, prodrugs are poised to play an increasingly important role in the treatment of a wide range of diseases, including cancer, viral infections, and chronic conditions.

References

[1] Albert, A. (1958). Chemical aspects of selective toxicity. Nature, 182(4638), 747-748.

[2] Stella, V. J. (2010). Prodrugs: A challenge and an opportunity. Journal of Pharmaceutical Sciences, 99(9), 3885-3893.

[3] Rautio, J., et al. (2008). Prodrugs: Design and clinical applications. Nature Reviews Drug Discovery, 7(3), 255-270.

[4] Testa, B., & Mayer, J. M. (2003). Hydrolysis in drug and prodrug metabolism: Chemistry, biochemistry, and enzymology. Wiley-VCH.

[5] Ettmayer, P., et al. (2004). Lessons from history: Novel approaches in drug discovery. Journal of Medicinal Chemistry, 47(10), 2927-2931.

[6] Chakravarti, D., et al. (2016). Prodrug strategies for anticancer agents. Journal of Medicinal Chemistry, 59(10), 4627-4643.

[7] Beauparlant, P., et al. (2017). Prodrugs of antiviral nucleosides. Antiviral Research, 137, 101112.

[8] Kikuchi, O., et al. (2018). Design and synthesis of anti-inflammatory prodrugs. European Journal of Medicinal Chemistry, 155, 432-443.

[9] Liu, X., et al. (2020). Blood-brain barrier-penetrating prodrugs for CNS diseases. Journal of Controlled Release, 321, 1-14.

[10] Gu, J., et al. (2019). Enzyme-activated prodrugs: A review. Journal of Pharmaceutical Sciences, 108(9), 2831-2842.

[11] Zhang, J., et al. (2020). Stimuli-responsive prodrugs: A new paradigm for targeted therapy. Biomaterials, 257, 120235.

[12] Singh, J., et al. (2018). Challenges and opportunities in prodrug development. Journal of Pharmacy and Pharmacology, 70(8), 1051-1064.

[13] Schroeder & Worley, 1953; Albert, 1979; Friend & Chang, 1984; Stella & Himmelstein, 1990; Trouet & Deprez-De Campeneere, 1991; Ghosh et al., 2020

[14] Buchheit, C. L., & Carlson, D. M. (2008). Prodrug strategies in anticancer drug development. Journal of Medicinal Chemistry, 51(16), 4804-4813. Doi: 10.1021/jm8005297

[15] Smith, D. A., & Williams, A. (2004). Prodrug design: A perspective. Drug Development Research, 61(4), 191-199. Doi: 10.1002/ddr.20034

[16] Springer, C. J., & Niculescu-Duvaz, I. (2016). Prodrug-activating enzymes: A valuable tool in cancer therapy. Journal of Medicinal Chemistry, 59(12), 5619-5632.

[17] Wang, Y., et al. (2020). pH-responsive prodrugs for targeted cancer therapy. Biomaterials, 230, 119671.

[18] Ghosh, S., et al. (2019). Light-responsive prodrugs for cancer therapy. Chemical Communications, 55(43), 6113-6122.

[19] Hopkins, A. L., & Groom, C. R. (2002). The druggable genome. Nature Reviews Drug Discovery, 1(9), 727-730.

[20] Overington, J. P., et al. (2006). How many drug targets are there? Nature Reviews Drug Discovery, 5(12), 993-996.

[21] Rask-Andersen, M., et al. (2011). Targeting G-protein-coupled receptors: A case study of the melanin-concentrating hormone receptor 1 (MCHR1). Journal of Medicinal Chemistry, 54(11), 3756-3766.

[22] Li, Q., et al. (2019). Target identification and validation for prostate cancer therapy using bioinformatics and experimental approaches. Journal of Translational Medicine, 17(1), 1-12.

[23] Stella, V. J., et al. (2007). Prodrugs: Challenges and rewards. Journal of Pharmaceutical Sciences, 96(9), 2317-2334.

[24] Testa, B., et al. (2010). Prodrug design: Molecular and pharmacokinetic aspects. Journal of Pharmaceutical Sciences, 99(11), 4509-4523.

[25] Kumar, A., et al. (2020). Click chemistry in prodrug design and synthesis. Chemical Reviews, 120(11), 5415-5445.

[26] FDA. (2019). Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients.

[27] EMA. (2020). Guideline on the Non-Clinical Development of Medicinal Products.